Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 02 Oct, 17:47 UTC

Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical cream that is currently…

science

Sources

• T2Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA SubmissionsFierce Biotech / Fierce Healthcare / MedCity / GEN02 Oct, 17:47